(Q39471203)

12 September 2017

The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

12 September 2017

1 reference

1 reference

1 reference

inferred from title

United States of America

1 reference

5

Maria Stepanova

1 reference

12 September 2017

Zobair M Younossi

1

1 reference

12 September 2017

Deirdre Blissett

2

1 reference

12 September 2017

Robert Blissett

3

1 reference

12 September 2017

Linda Henry

4

1 reference

12 September 2017

Youssef Younossi

6

1 reference

12 September 2017

Andrei Racila

7

1 reference

12 September 2017

Sharon Hunt

8

1 reference

12 September 2017

Rachel Beckerman

9

1 reference

12 September 2017

language of work or name

English

0 references

publication date

20 August 2016

1 reference

12 September 2017

1 reference

12 September 2017

64

1 reference

12 September 2017

1577-1586

1 reference

12 September 2017

5

1 reference

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

12 September 2017

1 reference

Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World

21 January 2018

1 reference

The Natural Course of Non-Alcoholic Fatty Liver Disease

21 January 2018

1 reference

Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality

21 January 2018

1 reference

Epidemiology and natural history of non-alcoholic fatty liver disease.

21 January 2018

1 reference

Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis.

21 January 2018

1 reference

Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

Nonalcoholic fatty liver disease in patients with type 2 diabetes

21 January 2018

1 reference

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference

Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.

21 January 2018

1 reference

Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study

21 January 2018

1 reference

Hepatocellular carcinoma in noncirrhotic livers is associated with steatosis rather than steatohepatitis: potential implications for pathogenesis.

21 January 2018

1 reference

Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States

21 January 2018

1 reference

Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease

21 January 2018

1 reference

Reliability and validity of the Chronic Liver Disease Questionnaire (CLDQ) in adults with non-alcoholic steatohepatitis (NASH).

21 January 2018

1 reference

Trends in outpatient resource utilizations and outcomes for Medicare beneficiaries with nonalcoholic fatty liver disease.

21 January 2018

1 reference

Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis

21 January 2018

1 reference

Long-term follow-up of patients with NAFLD and elevated liver enzymes

21 January 2018

1 reference

Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection

21 January 2018

1 reference

Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies

21 January 2018

1 reference

The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.

21 January 2018

1 reference

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

21 January 2018

1 reference

Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection

21 January 2018

1 reference

Health-state utilities in liver disease: a systematic review.

21 January 2018

1 reference

Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany--an application of the efficiency frontier approach

21 January 2018

1 reference

Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C

21 January 2018

1 reference

Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL).

21 January 2018

1 reference

Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold

21 January 2018

1 reference

21 January 2018

1 reference

Long-term improvement in health-related quality of life after orthotopic liver transplantation.

21 January 2018

1 reference

Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection

21 January 2018

1 reference

A generic model for the assessment of disease epidemiology: the computational basis of DisMod II

21 January 2018

1 reference

Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease

21 January 2018

1 reference

Calibrating models in economic evaluation: a seven-step approach.

21 January 2018

1 reference

Anthropometric and clinical factors associated with mortality in subjects with nonalcoholic fatty liver disease

21 January 2018

1 reference

7 January 2021

Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality

1 reference

7 January 2021

Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

7 January 2021

Spanish recommendations on economic evaluation of health technologies

1 reference

7 January 2021

The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.28785

1 reference

12 September 2017

1 reference